Table of Contents Author Guidelines Submit a Manuscript
Journal of Pathogens
Volume 2011, Article ID 347969, 6 pages
http://dx.doi.org/10.4061/2011/347969
Clinical Study

Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid

1PharmD, BCPS, Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, 650 Clinic Drive, Room 2100, Mobile, AL 36688, USA
2PharmD, MBA, BCPS AQ-ID, Huntsville Hospital Department of Pharmacy, 101 Sivley Road, Huntsville, AL 35801, USA

Received 23 July 2010; Revised 24 September 2010; Accepted 1 October 2010

Academic Editor: Kendra Rumbaugh

Copyright © 2011 Bradley M. Wright and Edward H. Eiland. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. J. Moet, R. N. Jones, D. J. Biedenbach, M. G. Stilwell, and T. R. Fritsche, “Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004),” Diagnostic Microbiology and Infectious Disease, vol. 57, no. 1, pp. 7–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. P. Rennie, R. N. Jones, and A. H. Mutnick, “Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000),” Diagnostic Microbiology and Infectious Disease, vol. 45, no. 4, pp. 287–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Anderson, D. J. Sexton, Z. A. Kanafani, G. Auten, and K. S. Kaye, “Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus,” Infection Control and Hospital Epidemiology, vol. 28, no. 9, pp. 1047–1053, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. S. Awad, S. I. Elhabash, L. Lee, B. Farrow, and D. H. Berger, “Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy,” American Journal of Surgery, vol. 194, no. 5, pp. 606–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. D. Holmberg, S. L. Solomon, and P. A. Blake, “Health and economic impacts of antimicrobial resistance,” Reviews of Infectious Diseases, vol. 9, no. 6, pp. 1065–1078, 1987. View at Google Scholar · View at Scopus
  6. R. M. Klevens, J. R. Edwards, F. C. Tenover, L. C. McDonald, T. Horan, and R. Gaynes, “Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003,” Clinical Infectious Diseases, vol. 42, no. 3, pp. 389–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Boyce, M. Landry, T. R. Deetz, and H. L. DuPont, “Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections,” Infection Control, vol. 2, no. 2, pp. 110–116, 1981. View at Google Scholar · View at Scopus
  8. J. J. Engemann, Y. Carmeli, S. E. Cosgrove et al., “Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection,” Clinical Infectious Diseases, vol. 36, no. 5, pp. 592–598, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Wang, J. F. Hindler, K. W. Ward, and D. A. Bruckner, “Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period,” Journal of Clinical Microbiology, vol. 44, no. 11, pp. 3883–3886, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Steinkraus, R. White, and L. Friedrich, “Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 4, pp. 788–794, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Davis, P. S. McKinnon, L. M. Hall et al., “Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes,” Pharmacotherapy, vol. 27, no. 12, pp. 1611–1618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. D. Arbeit, D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein, “The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections,” Clinical Infectious Diseases, vol. 38, no. 12, pp. 1673–1681, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Google Scholar · View at Scopus
  14. R. L. Page II and J. Mark Ruscin, “The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use,” American Journal Geriatric Pharmacotherapy, vol. 4, no. 4, pp. 297–305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. T. Micek, “Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections,” Clinical Infectious Diseases, vol. 45, supplement 3, pp. S184–S190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, and C. Knirsch, “Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 6, pp. 2260–2266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. M. F. Itani, J. Weigelt, J. Z. Li, and S. Duttagupta, “Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA),” International Journal of Antimicrobial Agents, vol. 26, no. 6, pp. 442–448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. S. McKinnon, S. V. Sorensen, L. Z. Liu, and K. M. F. Itani, “Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and sof-tissue infections,” Annals of Pharmacotherapy, vol. 40, no. 6, pp. 1017–1023, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. L. Stevens, D. Herr, H. Lampiris, J. L. Hunt, D. H. Batts, and B. Hafkin, “Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections,” Clinical Infectious Diseases, vol. 34, no. 11, pp. 1481–1490, 2002. View at Publisher · View at Google Scholar · View at Scopus